Abstract 198P
Background
Women with breast cancer with impaired immunity develop life-threatening clinical disease. Findings of tumor-associated lymphocytes in tumor specimens are explicit evidence of immunologic sensitivity to this. Despite several treatment modalities, the majority of patients eventually relapse. However, immunotherapy – a new promising modality for treatment - has been advocated to command disease progress. Cancer immunoediting provided insights that the immune system has both immune surveillance and tumor promotion effects during cancer development. Anti-tumor immune response requires involvement of both CD4+ and CD8+ T cells. Thus, for better understanding the roles of CD4+ CD8 and regulatory T cells in pathogenesis and progression of breast cancer, the following study was designed to be conducted in clinical patients with breast cancer. 1-To determine expression of FOXP3 CD25, CD4, CD8 before therapy in blood, and tumor tissue. 2-Impact of surgery and chemotherapy on immunological status of tumour in breast cancer patients.
Methods
This was a prospective observational pilot study. Patients: N=30, locally advanced and metastatic breast cancer patients receiving chemotherapy as first modality of treatment (NACT group). N=30, early breast cancer patients receiving surgery as first modality of treatment (Upfront surgery). Control: N=30, Sex matched group undergoing surgery for benign breast disease.
Results
In the pre-treatment group lower expression of CD4 and higher CD8 and Tregs were found as the disease progresses. After upfront surgery CD4 counts increase with decrease of CD8 and Tregs cells. There was no change in CD4 in the control after surgery with positive correlation in CD8 and Tregs. Higher CD4 counts with lower CD8 and Tregs were found in patients after NACT.
Conclusions
T-cell subgroups in breast cancer patients undergo dynamic, significant changes during surgery and chemotherapy. Comprehensive analysis of characteristic T cell repertoire in breast cancer has depicted a landscape of possibilities of developing a blood-based therapeutic or preventive (vaccine) modality to enhance the armamentarium against this cancer.
Legal entity responsible for the study
AIIMS.
Funding
AIIMS New Delhi.
Disclosure
The author declared no conflicts of interest.
Resources from the same session
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract